JP2018512380A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018512380A5 JP2018512380A5 JP2017542486A JP2017542486A JP2018512380A5 JP 2018512380 A5 JP2018512380 A5 JP 2018512380A5 JP 2017542486 A JP2017542486 A JP 2017542486A JP 2017542486 A JP2017542486 A JP 2017542486A JP 2018512380 A5 JP2018512380 A5 JP 2018512380A5
- Authority
- JP
- Japan
- Prior art keywords
- tumor antigen
- individual
- antigen peptides
- cancer
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 136
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 122
- 238000000034 method Methods 0.000 claims description 98
- 239000000427 antigen Substances 0.000 claims description 97
- 108091007433 antigens Proteins 0.000 claims description 97
- 102000036639 antigens Human genes 0.000 claims description 97
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 87
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 61
- 210000004443 dendritic cell Anatomy 0.000 claims description 53
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 30
- 201000011510 cancer Diseases 0.000 claims description 28
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 16
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 16
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 16
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 16
- 108091008874 T cell receptors Proteins 0.000 claims description 10
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 10
- 239000003112 inhibitor Substances 0.000 claims description 10
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 9
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 8
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 8
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims description 8
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims description 8
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims description 8
- 102000017578 LAG3 Human genes 0.000 claims description 8
- 101150030213 Lag3 gene Proteins 0.000 claims description 8
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims description 8
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims description 8
- 229940126546 immune checkpoint molecule Drugs 0.000 claims description 8
- 230000000869 mutational effect Effects 0.000 claims description 8
- 238000012163 sequencing technique Methods 0.000 claims description 8
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 7
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 7
- 101000840545 Bacillus thuringiensis L-isoleucine-4-hydroxylase Proteins 0.000 claims description 7
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 7
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 7
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 7
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 7
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims description 7
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 claims description 7
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 claims description 7
- 101001037255 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Indoleamine 2,3-dioxygenase Proteins 0.000 claims description 7
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims description 7
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims description 6
- 230000001464 adherent effect Effects 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 230000000890 antigenic effect Effects 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 6
- 230000028993 immune response Effects 0.000 claims description 6
- 230000035772 mutation Effects 0.000 claims description 6
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 claims description 4
- 238000010367 cloning Methods 0.000 claims description 4
- 210000001616 monocyte Anatomy 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 102100023635 Alpha-fetoprotein Human genes 0.000 claims description 3
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 claims description 3
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims description 3
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims description 3
- 108010058546 Cyclin D1 Proteins 0.000 claims description 3
- 102000006311 Cyclin D1 Human genes 0.000 claims description 3
- 102100032530 Glypican-3 Human genes 0.000 claims description 3
- 102100027755 Histone-lysine N-methyltransferase 2C Human genes 0.000 claims description 3
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims description 3
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims description 3
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims description 3
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 claims description 3
- 101001014668 Homo sapiens Glypican-3 Proteins 0.000 claims description 3
- 101001008892 Homo sapiens Histone-lysine N-methyltransferase 2C Proteins 0.000 claims description 3
- 101000990912 Homo sapiens Matrilysin Proteins 0.000 claims description 3
- 101000587058 Homo sapiens Methylenetetrahydrofolate reductase Proteins 0.000 claims description 3
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims description 3
- 101000883798 Homo sapiens Probable ATP-dependent RNA helicase DDX53 Proteins 0.000 claims description 3
- 101000735463 Homo sapiens Protein mono-ADP-ribosyltransferase PARP4 Proteins 0.000 claims description 3
- 101710123134 Ice-binding protein Proteins 0.000 claims description 3
- 101710082837 Ice-structuring protein Proteins 0.000 claims description 3
- -1 MET Proteins 0.000 claims description 3
- 102100030417 Matrilysin Human genes 0.000 claims description 3
- 102100029684 Methylenetetrahydrofolate reductase Human genes 0.000 claims description 3
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 claims description 3
- 102100038236 Probable ATP-dependent RNA helicase DDX53 Human genes 0.000 claims description 3
- 102100034931 Protein mono-ADP-ribosyltransferase PARP4 Human genes 0.000 claims description 3
- 102100037421 Regulator of G-protein signaling 5 Human genes 0.000 claims description 3
- 101710140403 Regulator of G-protein signaling 5 Proteins 0.000 claims description 3
- 108010002687 Survivin Proteins 0.000 claims description 3
- 101710107540 Type-2 ice-structuring protein Proteins 0.000 claims description 3
- 108091008605 VEGF receptors Proteins 0.000 claims description 3
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 3
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 claims description 3
- 238000003501 co-culture Methods 0.000 claims description 3
- 230000004069 differentiation Effects 0.000 claims description 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 claims description 2
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 102100021688 Rho guanine nucleotide exchange factor 5 Human genes 0.000 claims 1
- 101710149792 Triosephosphate isomerase, chloroplastic Proteins 0.000 claims 1
- 101710195516 Triosephosphate isomerase, glycosomal Proteins 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 20
- 108090000695 Cytokines Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 102100030708 GTPase KRas Human genes 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 1
- 102000003812 Interleukin-15 Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 102100030703 Interleukin-22 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 102000000704 Interleukin-7 Human genes 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 102000004503 Perforin Human genes 0.000 description 1
- 108010056995 Perforin Proteins 0.000 description 1
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 108010074108 interleukin-21 Proteins 0.000 description 1
- 229930192851 perforin Natural products 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2015/074227 | 2015-03-13 | ||
| PCT/CN2015/074227 WO2016145578A1 (en) | 2015-03-13 | 2015-03-13 | Methods of cancer treatment using activated t cells |
| PCT/CN2016/076165 WO2016146035A1 (en) | 2015-03-13 | 2016-03-11 | Methods of cancer treatment using activated t cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021009572A Division JP7244117B2 (ja) | 2015-03-13 | 2021-01-25 | 活性化ｔ細胞を用いるがん治療の方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018512380A JP2018512380A (ja) | 2018-05-17 |
| JP2018512380A5 true JP2018512380A5 (https=) | 2019-04-18 |
| JP6856534B2 JP6856534B2 (ja) | 2021-04-07 |
Family
ID=56918222
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017542486A Active JP6856534B2 (ja) | 2015-03-13 | 2016-03-11 | 活性化ｔ細胞を用いるがん治療の方法 |
| JP2021009572A Active JP7244117B2 (ja) | 2015-03-13 | 2021-01-25 | 活性化ｔ細胞を用いるがん治療の方法 |
| JP2022092917A Withdrawn JP2022111272A (ja) | 2015-03-13 | 2022-06-08 | 活性化ｔ細胞を用いるがん治療の方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021009572A Active JP7244117B2 (ja) | 2015-03-13 | 2021-01-25 | 活性化ｔ細胞を用いるがん治療の方法 |
| JP2022092917A Withdrawn JP2022111272A (ja) | 2015-03-13 | 2022-06-08 | 活性化ｔ細胞を用いるがん治療の方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US10967054B2 (https=) |
| EP (2) | EP4219690A3 (https=) |
| JP (3) | JP6856534B2 (https=) |
| KR (2) | KR20240069809A (https=) |
| CN (3) | CN107735492B (https=) |
| CA (1) | CA2975602A1 (https=) |
| IL (2) | IL253795B (https=) |
| RU (1) | RU2729362C2 (https=) |
| WO (2) | WO2016145578A1 (https=) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015109391A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
| WO2016145578A1 (en) | 2015-03-13 | 2016-09-22 | Syz Cell Therapy Co. | Methods of cancer treatment using activated t cells |
| GB201516047D0 (en) | 2015-09-10 | 2015-10-28 | Cancer Rec Tech Ltd | Method |
| RU2729116C2 (ru) | 2015-12-16 | 2020-08-04 | Гритстоун Онколоджи, Инк. | Идентификация, производство и применение неоантигенов |
| US20170224796A1 (en) | 2016-02-05 | 2017-08-10 | Xeme Biopharma Inc. | Therapeutic Cancer Vaccine Containing Tumor-Associated Neoantigens and Immunostimulants in a Delivery System |
| JP7185530B2 (ja) | 2016-06-13 | 2022-12-07 | トルク セラピューティクス， インコーポレイテッド | 免疫細胞機能を促進するための方法および組成物 |
| BR112019006652A2 (pt) * | 2016-10-13 | 2019-07-02 | Juno Therapeutics Inc | métodos e composições para imunoterapia envolvendo moduladores da via metabólica do triptofano |
| JP7080458B2 (ja) * | 2016-10-14 | 2022-06-06 | 国立大学法人京都大学 | Ｐｄ－１経路阻害薬の薬剤感受性を判定する方法 |
| WO2018071576A1 (en) * | 2016-10-14 | 2018-04-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Treatment of tumors by inhibition of cd300f |
| GB201618291D0 (en) * | 2016-10-28 | 2016-12-14 | Bergen Teknologioverf�Ring As | Novel immunotherapeutic treatments for tumours |
| CN109952308B (zh) * | 2016-11-29 | 2022-09-23 | 武汉华大吉诺因生物科技有限公司 | 多肽及其应用 |
| WO2018102761A1 (en) * | 2016-12-02 | 2018-06-07 | City Of Hope | Methods for manufacturing and expanding t cells expressing chimeric antigen receptors and other receptors |
| UY37594A (es) * | 2017-02-07 | 2018-08-31 | Univ Saitama Medical | Biomarcador inmunologico para predecir el efecto clinico de inmunoterapia del cancer |
| US11229668B2 (en) | 2017-02-07 | 2022-01-25 | Nantcell, Inc. | Maximizing T-cell memory and compositions and methods therefor |
| JP2020506943A (ja) * | 2017-02-07 | 2020-03-05 | メモリアル スローン ケタリング キャンサー センター | 養子免疫療法における抗原特異的ｔ細胞と組み合わせた免疫チェックポイント調節剤の使用 |
| JP7763588B2 (ja) * | 2017-09-05 | 2025-11-04 | グリットストーン バイオ インコーポレイテッド | Ｔ細胞療法用の新生抗原の特定法 |
| JP7285828B2 (ja) | 2017-09-05 | 2023-06-02 | トルク セラピューティクス， インコーポレイテッド | 治療用タンパク質組成物ならびにその作製および使用方法 |
| KR20260039788A (ko) | 2017-10-10 | 2026-03-20 | 시애틀 프로젝트 코포레이션 | 핫스팟을 이용한 신생항원 동정 |
| EP3704268B1 (en) | 2017-11-03 | 2025-01-22 | Guardant Health, Inc. | Normalizing tumor mutation burden |
| CN111801415A (zh) * | 2017-11-06 | 2020-10-20 | 路德维格癌症研究院 | 扩增淋巴细胞的方法 |
| CA3083097A1 (en) | 2017-11-22 | 2019-05-31 | Gritstone Oncology, Inc. | Reducing junction epitope presentation for neoantigens |
| US10363008B2 (en) * | 2017-11-27 | 2019-07-30 | Canon Medical Systems Usa, Inc. | Computed tomography perfusion (CTP) method and apparatus using blood flow for discriminating types of cancer |
| US20200368336A1 (en) * | 2017-12-01 | 2020-11-26 | Shanghai Jenomed Biotech Co., Ltd. | Method for preparing personalized cancer vaccine |
| CN111670040A (zh) * | 2018-01-08 | 2020-09-15 | 密歇根大学董事会 | Aldh1抗原冲击树突状细胞 |
| WO2019183924A1 (en) * | 2018-03-30 | 2019-10-03 | Syz Cell Therapy Co. | Improved multiple antigen specific cell therapy methods |
| WO2019196088A1 (en) | 2018-04-13 | 2019-10-17 | Syz Cell Therapy Co. | Methods of obtaining tumor-specific t cell receptors |
| WO2019196087A1 (en) | 2018-04-13 | 2019-10-17 | Syz Cell Therapy Co. | Methods of cancer treatment using tumor antigen-specific t cells |
| CN112512538A (zh) * | 2018-05-18 | 2021-03-16 | 国家儿童医疗中心 | 改进的靶向t细胞疗法 |
| JP7466519B2 (ja) | 2018-07-23 | 2024-04-12 | ガーダント ヘルス， インコーポレイテッド | 腫瘍遺伝子変異量を腫瘍割合およびカバレッジによって調整するための方法およびシステム |
| CA3106562A1 (en) | 2018-07-26 | 2020-01-30 | Frame Pharmaceuticals B.V. | Off-the-shelf cancer vaccines |
| WO2020022899A1 (en) | 2018-07-26 | 2020-01-30 | Frame Pharmaceuticals B.V. | Cancer vaccines for breast cancer |
| US20210172961A1 (en) * | 2018-07-27 | 2021-06-10 | Board Of Regents, The University Of Texas System | Methods for identifying rna editing-derived epitopes that elicit immune responses in cancer |
| CN109294997B (zh) * | 2018-09-30 | 2020-09-25 | 北京鼎成肽源生物技术有限公司 | 一种lrfft1细胞 |
| CN109337873A (zh) * | 2018-09-30 | 2019-02-15 | 北京鼎成肽源生物技术有限公司 | 一种lrff细胞 |
| CN109295106B (zh) * | 2018-09-30 | 2020-07-24 | 北京鼎成肽源生物技术有限公司 | 一种hafft1细胞 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| AU2019373241A1 (en) * | 2018-10-29 | 2021-06-10 | Genocea Biosciences, Inc. | Treatment methods |
| WO2020106982A1 (en) * | 2018-11-21 | 2020-05-28 | Board Of Regents, The University Of Texas System | Methods of overcoming resistance to immune checkpoint inhibitors |
| US20220296642A1 (en) * | 2018-12-04 | 2022-09-22 | Nantomics, Llc | Methods of Making Therapeutic T Lymphocytes |
| EP3908293A4 (en) * | 2019-01-07 | 2023-01-11 | Children's National Medical Center | EX VIVO ACTIVATED T LYMPHOCYTE COMPOSITIONS AND METHODS OF USE THEREOF |
| WO2020160285A1 (en) * | 2019-02-01 | 2020-08-06 | The Board Of Trustees Of The Leland Stanford Junior University | SIRPα EXPRESSION ON T CELLS IS A BIOMARKER FOR FUNCTIONAL T CELLS DURING EXHAUSTION |
| CA3131777A1 (en) * | 2019-03-01 | 2020-09-10 | Flow Pharma Inc. | Design, manufacture, and use of personalized cancer vaccines |
| CN111751545A (zh) * | 2019-03-28 | 2020-10-09 | 中国科学院上海药物研究所 | 一种筛选pd-l1/pd-1检测点抑制剂的方法 |
| WO2020227279A1 (en) * | 2019-05-06 | 2020-11-12 | Hasumi International Research Foundation | Therapy and methods of introducing immature dendritic cells and/or cytotoxic t lymphocyte and anti pd-1 / pd-l1 antibody for treatment of tumors |
| KR20220026575A (ko) * | 2019-06-25 | 2022-03-04 | 시티 오브 호프 | Pdl1 양성 nk 세포 암 치료 |
| CN114599378A (zh) * | 2019-10-31 | 2022-06-07 | 公立大学法人福岛县立医科大学 | 用于肿瘤的治疗和/或预防的组合物 |
| MX2019015508A (es) | 2019-12-18 | 2021-06-21 | Univ Guadalajara | Nanopartículas para el tratamiento del cáncer. |
| CN111337681A (zh) * | 2020-03-20 | 2020-06-26 | 上海东方肝胆外科医院 | 评估肝细胞癌预后的标志物、试剂盒及方法 |
| WO2021219990A1 (en) * | 2020-04-28 | 2021-11-04 | Achilles Therapeutics Uk Limited | T cell therapy |
| CN116018158A (zh) * | 2020-04-30 | 2023-04-25 | 转化基因组学研究所 | 新抗原知情的肿瘤浸润性淋巴细胞癌免疫疗法 |
| CN111575232A (zh) * | 2020-05-15 | 2020-08-25 | 暨南大学 | JQ1在抑制T淋巴细胞PD-1和/或Tim-3表达中的应用 |
| CN111647563A (zh) * | 2020-08-06 | 2020-09-11 | 北京翊博普惠生物科技发展有限公司 | 靶向Survivin全抗原的DC细胞、CTL细胞及其制备方法和应用 |
| WO2022059780A1 (ja) * | 2020-09-18 | 2022-03-24 | サイアス株式会社 | ｉＰＳ細胞を介する再生Ｔ細胞の製造方法 |
| CN112501308B (zh) * | 2020-11-30 | 2025-10-10 | 中国水产科学研究院珠江水产研究所 | 一组鳖科动物线粒体全基因组扩增通用引物 |
| CN114045272B (zh) * | 2021-03-24 | 2024-12-06 | 深圳市新靶向生物科技有限公司 | 一种与乳腺癌驱动基因突变相关的抗原肽组合及其应用 |
| TW202317754A (zh) * | 2021-06-30 | 2023-05-01 | 日商諾瓦瑟拉姆股份有限公司 | 製備含有血中循環腫瘤細胞之樣品之方法 |
| EP4422668A1 (en) * | 2021-10-25 | 2024-09-04 | Ellennbe GmbH | Pharmaceutical composition and kit comprising an immunomodulatory substance for treating diseases |
| KR102732911B1 (ko) * | 2021-12-29 | 2024-11-20 | 의료법인 명지의료재단 | K-ras 특이적 활성화 T 세포를 포함하는 유방암의 예방 및 치료용 약제학적 조성물 및 이의 제조방법 |
| KR102732913B1 (ko) * | 2021-12-29 | 2024-11-20 | 의료법인 명지의료재단 | K-ras 특이적 활성화 T 세포를 포함하는 흑색종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법 |
| KR102732909B1 (ko) * | 2021-12-29 | 2024-11-20 | 의료법인 명지의료재단 | K-ras 특이적 활성화 T 세포를 포함하는 폐 유두상 선암종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법 |
| KR102732912B1 (ko) * | 2021-12-29 | 2024-11-20 | 의료법인 명지의료재단 | K-ras 특이적 활성화 T 세포를 포함하는 폐 선암종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법 |
| KR102732910B1 (ko) * | 2021-12-29 | 2024-11-20 | 의료법인 명지의료재단 | K-ras 특이적 활성화 T 세포를 포함하는 대장암의 예방 및 치료용 약제학적 조성물 및 이의 제조방법 |
| CN115998851A (zh) * | 2022-12-28 | 2023-04-25 | 四川康德赛医疗科技有限公司 | 一种个体化mRNA组合物、载体、mRNA疫苗及其应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5388946A (en) | 1988-01-20 | 1995-02-14 | Grau Gmbh & Co. | Systems and methods for the automated archiving and retrieval of computer data storage cassettes |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US6080409A (en) | 1995-12-28 | 2000-06-27 | Dendreon Corporation | Immunostimulatory method |
| JP2000505650A (ja) * | 1996-02-08 | 2000-05-16 | アメリカ合衆国 | 樹状突起細胞を形質転換し、そしてｔ細胞を活性化するための方法及び組成物 |
| US20050170503A1 (en) * | 1997-02-27 | 2005-08-04 | University Of Pittsburgh | In vitro induction of antigen-specific T-cells using dendritic cell-tumor cell or dendritic cell-viral cell derived immunogens |
| US20040110283A1 (en) | 1997-02-27 | 2004-06-10 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Induction of tumor and viral immunity using antigen presenting cell co-culture products and fusion products |
| WO2000057705A1 (en) | 1999-03-31 | 2000-10-05 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | In vitro induction of antigen-specific t-cells using dendritic cell-tumor cell or dendritic cell-viral cell derived immunogens |
| CA2386270A1 (en) | 1999-10-15 | 2001-04-26 | University Of Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
| DK1224264T3 (da) | 1999-10-15 | 2010-05-10 | Baylor Res Inst | Anvendelse af allogene cellelinjer til at belaste antigenpræsenterende celler til at fremkomme med immunresponser |
| US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
| AU2001275474A1 (en) | 2000-06-12 | 2001-12-24 | Akkadix Corporation | Materials and methods for the control of nematodes |
| JP2004501631A (ja) | 2000-06-28 | 2004-01-22 | ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー | Ｐｄ−ｌ２分子：新規ｐｄ−１リガンドおよびその使用 |
| CA2448599A1 (en) | 2001-04-27 | 2002-11-07 | Invitrogen Corporation | Maturation of antigen-presenting cells using activated t cells |
| KR20080109717A (ko) | 2005-12-08 | 2008-12-17 | 노쓰웨스트 바이오써라퓨틱스, 인크. | 미성숙 단핵구성 수지상 세포의 활성화를 유도하기 위한조성물 및 방법 |
| EP3375868A1 (en) | 2007-11-08 | 2018-09-19 | Dana Farber Cancer Institute, Inc. | Stimulation of anti-tumor immunity using dendritic cell/tumor cell fusions and anti-cd3/cd28 |
| HUE029914T2 (en) | 2008-04-03 | 2017-04-28 | Cb Biotechnologies Inc | Amplicon-saving multiplex polymerase chain reaction for amplification of multiple targets |
| EP3101122B1 (en) * | 2009-08-24 | 2023-06-14 | Baylor College of Medicine | Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses |
| JP5816627B2 (ja) | 2009-10-27 | 2015-11-18 | イミュニカム・エイビイ | 抗原特異的ｔ細胞の増殖のための方法 |
| JP6293674B2 (ja) * | 2012-01-13 | 2018-03-14 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 構造化ポリマー装置におけるｔｌｒアゴニストの制御送達 |
| KR20160093012A (ko) * | 2013-11-05 | 2016-08-05 | 코그네이트 바이오서비시즈, 인코포레이티드 | 암 치료를 위한 체크포인트 억제제 및 치료제의 배합물 |
| WO2016145578A1 (en) | 2015-03-13 | 2016-09-22 | Syz Cell Therapy Co. | Methods of cancer treatment using activated t cells |
| WO2016154628A1 (en) | 2015-03-26 | 2016-09-29 | Xiuli Wang | Bi-specific targeted chimeric antigen receptor t cells |
| US20180171294A1 (en) | 2015-03-26 | 2018-06-21 | The Trustees Of The University Of Pennsylvania | In vitro artificial lymph node method for sensitization and expansion of t cells for therapy and epitope mapping |
| CN104946588A (zh) | 2015-07-07 | 2015-09-30 | 英普乐孚生物技术(上海)有限公司 | 一种抗原特异性t淋巴细胞的分离和高效扩增培养方法 |
| CN106645677B (zh) | 2016-11-15 | 2019-08-09 | 恒瑞源正（上海）生物科技有限公司 | 体外检测肿瘤新生抗原特异性t细胞的方法、试剂盒以及肿瘤疫苗 |
| HUE058957T2 (hu) | 2016-12-08 | 2022-10-28 | Immatics Biotechnologies Gmbh | Új T-sejt receptorok és velük végzett immunterápia |
| WO2019183924A1 (en) | 2018-03-30 | 2019-10-03 | Syz Cell Therapy Co. | Improved multiple antigen specific cell therapy methods |
| WO2019196087A1 (en) | 2018-04-13 | 2019-10-17 | Syz Cell Therapy Co. | Methods of cancer treatment using tumor antigen-specific t cells |
| WO2019196088A1 (en) | 2018-04-13 | 2019-10-17 | Syz Cell Therapy Co. | Methods of obtaining tumor-specific t cell receptors |
-
2015
- 2015-03-13 WO PCT/CN2015/074227 patent/WO2016145578A1/en not_active Ceased
-
2016
- 2016-03-11 KR KR1020247014424A patent/KR20240069809A/ko active Pending
- 2016-03-11 RU RU2017134270A patent/RU2729362C2/ru active
- 2016-03-11 US US15/557,794 patent/US10967054B2/en active Active
- 2016-03-11 KR KR1020177028517A patent/KR102698909B1/ko active Active
- 2016-03-11 CN CN201680015221.3A patent/CN107735492B/zh active Active
- 2016-03-11 WO PCT/CN2016/076165 patent/WO2016146035A1/en not_active Ceased
- 2016-03-11 JP JP2017542486A patent/JP6856534B2/ja active Active
- 2016-03-11 EP EP23156772.8A patent/EP4219690A3/en active Pending
- 2016-03-11 CN CN202210482133.1A patent/CN115607659A/zh active Pending
- 2016-03-11 CA CA2975602A patent/CA2975602A1/en active Pending
- 2016-03-11 EP EP16764215.6A patent/EP3268465B1/en active Active
- 2016-03-11 CN CN202210483613.XA patent/CN115501331A/zh active Pending
-
2017
- 2017-08-02 IL IL253795A patent/IL253795B/en active IP Right Grant
-
2020
- 2020-12-08 US US17/115,620 patent/US11219675B2/en active Active
-
2021
- 2021-01-25 JP JP2021009572A patent/JP7244117B2/ja active Active
- 2021-03-17 US US17/204,846 patent/US11229689B2/en active Active
- 2021-06-06 IL IL283733A patent/IL283733A/en unknown
-
2022
- 2022-01-13 US US17/575,616 patent/US12312597B2/en active Active
- 2022-06-08 JP JP2022092917A patent/JP2022111272A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018512380A5 (https=) | ||
| Chaurio et al. | TGF-β-mediated silencing of genomic organizer SATB1 promotes Tfh cell differentiation and formation of intra-tumoral tertiary lymphoid structures | |
| RU2017134270A (ru) | Способы лечения рака с применением активированных t-клеток | |
| Xue et al. | Induced pluripotent stem cell-derived engineered T cells, natural killer cells, macrophages, and dendritic cells in immunotherapy | |
| Tang et al. | Prognostic and therapeutic TILs of cervical cancer—Current advances and future perspectives | |
| D’Alise et al. | Adenoviral-based vaccine promotes neoantigen-specific CD8+ T cell stemness and tumor rejection | |
| Kooreman et al. | Autologous iPSC-based vaccines elicit anti-tumor responses in vivo | |
| Parkhurst et al. | Isolation of T-cell receptors specifically reactive with mutated tumor-associated antigens from tumor-infiltrating lymphocytes based on CD137 expression | |
| Ye et al. | An armed oncolytic virus enhances the efficacy of tumor-infiltrating lymphocyte therapy by converting tumors to artificial antigen-presenting cells in situ | |
| Marigo et al. | T cell cancer therapy requires CD40-CD40L activation of tumor necrosis factor and inducible nitric-oxide-synthase-producing dendritic cells | |
| Matsuzaki et al. | Direct tumor recognition by a human CD4+ T-cell subset potently mediates tumor growth inhibition and orchestrates anti-tumor immune responses | |
| Palucka et al. | Taming cancer by inducing immunity via dendritic cells | |
| Boudreau et al. | Engineering dendritic cells to enhance cancer immunotherapy | |
| Butler et al. | Human cell‐based artificial antigen‐presenting cells for cancer immunotherapy | |
| Weinstock et al. | Dendritic cell therapies for hematologic malignancies | |
| JP2021520849A5 (https=) | ||
| Sonntag et al. | Immune monitoring and TCR sequencing of CD4 T cells in a long term responsive patient with metastasized pancreatic ductal carcinoma treated with individualized, neoepitope-derived multipeptide vaccines: a case report | |
| Ochi et al. | Optimization of T-cell reactivity by exploiting TCR chain centricity for the purpose of safe and effective antitumor TCR gene therapy | |
| KR20200055808A (ko) | 항원-특이적 t 세포 식별, 농축, 및/또는 증식을 위한 시약 및 방법 | |
| JP2022513148A (ja) | Ｔ細胞の改変 | |
| Giannakopoulou et al. | AT cell receptor targeting a recurrent driver mutation in FLT3 mediates elimination of primary human acute myeloid leukemia in vivo | |
| Borges et al. | Trial watch: anticancer vaccination with dendritic cells | |
| Straetemans et al. | TCR Gene Transfer: MAGE‐C2/HLA‐A2 and MAGE‐A3/HLA‐DP4 Epitopes as Melanoma‐Specific Immune Targets | |
| Sundarasetty et al. | Lentivirus-induced dendritic cells for immunization against high-risk WT1+ acute myeloid leukemia | |
| Zhang et al. | Generation of mouse pluripotent stem cell–derived proliferating myeloid cells as an unlimited source of functional antigen-presenting cells |